Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2003

View Archived Issues

Beneficial effects reported for duloxetine in primary fibromyalgia

LJP-394 well tolerated in SLE patients with renal disease

Milnacipran as a potential therapy for FMS

Immunomodulatory effects of OM-89 in rheumatoid arthritis patients

Studies on lumiracoxib in rheumatoid arthritis presented at ACR meeting

Immunomodulating activity reported for LymphoStat-B in monkeys and SLE patients

Sankyo describes the isolation of a 2'-PDE inhibitor with utility in viral infections

First North American trial of Adhibit

Levaquin approved for five-day treatment of CAP

Millennium and Bayer alliance concludes

New inhibitors of ZAP-70, FAK and/or Syk designed at Novartis

Indian group identifies new antiallergic/antiasthmatic agents

Servier team presents new 5-HT2C antagonists for anxiety and other disorders

Apotex researchers prepare and test new factor XIIIa inhibitors

Two series of PDE7 inhibitors and their use presented by Warner-Lambert (Pfizer) scientists

Novel HIV integrase inhibitors claimed by Merck

Novartis describes new CCR3 antagonists with utility in asthma therapy

Sankyo intensifies development of anticancer drugs

Sifrol approved for the treatment of Parkinson's disease

Raptiva approved for chronic, moderate to severe plaque psoriasis

Approvable letter received for Ariflo

Canadian approval for Gleevec for newly diagnosed Ph+ CML

European enrollment commences in phase II trial for DAC:GLP-1

Development of KW-6002 temporarily suspended

Prodrugs of CO/CO2 associated with clinical and radiographic improvement in arthritis

Targeted therapy of AML with anti-FLT3 antibody under evaluation

Anticytokine drug in development at Kowa for oral therapy of arthritis

Microbially produced inhibitor of bacteria-specific enzyme discovered

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...